TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02013726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MBI Scan: The LumaGEM®
Description: The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®
Description: The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
Study: NCT00955266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Chloride
Description: Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 50cc delivered over 5 minutes
Study: NCT04405609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmAssist
Description: The usability study protocol include 3 ArmAssist systems (2 designed for the left hand and one for the right hand) that could not be used in parallel because the aim of the study was to bring the systems to the home environment during part of the evaluation.~The usability study is carried out in two phases:~1. First phase: 5 weeks.~2. Second phase: 3 weeks. Each phase included a week of training at the Hospital or IMIBIC facilities with a physiotherapist, and then 2 weeks at the patient's home, being the first one with the physiotherapist supervision and the second one by their own with the possibility of physiotherapist remote support.
Study: NCT02137031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini Link REAL-Time Transmitter
Description: Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
Study: NCT04548401

Intervention type: DRUG
Intervention: Antiplatelet Drug
Description: aspirin and/or clopidogrel or ticagrelor
Study: NCT03058549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Expectations
Description: Relationship education and referral services for expectant couples.
Study: NCT03389633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Study: NCT05129644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (24 mcg)
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (48 mcg)
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.
Study: NCT01706588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac sodium
Description: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
Study: NCT02024139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing Sugarless Gum
Description: Chewing sugar free gum three times per day for 5-10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using Mouthwash
Description: Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Using Mouthwash
Description: Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
Study: NCT02457468

Intervention type: DEVICE
Intervention: coflex
Study: NCT05117190

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Facial Allotransplantation
Study: NCT01964625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-CT Scan
Description: PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
Study: NCT01487265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 and Erlotinib
Description: BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
Study: NCT05129644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (90 mcg)
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (180 mcg)
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (225 mcg)
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (270 mcg)
Description: P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.
Study: NCT02613585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permethrin Impregnated Clothing
Description: Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
Study: NCT00742417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albutein 5%
Description: 18 Plasma Exchanges using Albutein 5%:~* three weeks of intensive treatment with two plasma exchanges per week~* six weeks of maintenance treatment with one weekly plasma exchange~* three months of maintenance treatment with one plasma exchange every two weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
Study: NCT01992835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grass pollen allergen extract
Description: Each subject will be challenged with a grass pollen allergen extract and with placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04070417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
Study: NCT01421953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-simulation and 4D PET-CT
Description: Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
Study: NCT04492501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma exchange
Description: 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma exchange
Description: 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma exchange
Description: 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
Study: NCT05129644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.
Study: NCT04169789

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)
Description: L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
Study: NCT04492501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of \> 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;~1. After 28 day of illness till 3 months~2. Symptom free 2 weeks prior to donation~3. Negative two consecutive PCRs any time between initial positivity and before donation~4. Anti SARS-CoV2 IgG positive, IgM negative~5. Fulfills healthy donor criteria as per WHO/AABB guidelines~6. Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Convalescent plasma as part of replacement therapy (200-400ml) if reported within 14 days of illness. An IgG titer of \> 1.320 will be considered suitable for use. It will be Collected from person previously infected with Covid-19 and meet following criteria;~1. After 28 day of illness till 3 months~2. Symptom free 2 weeks prior to donation~3. Negative two consecutive PCRs any time between initial positivity and before donation~4. Anti SARS-CoV2 IgG positive, IgM negative~5. Fulfills healthy donor criteria as per WHO/AABB guidelines~6. Volume of plasma to be collected: 900-1200 ml through Apheresis OR plasma separated from phlebotomy donation
Study: NCT04169789

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)
Description: L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)
Description: L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
Study: NCT02849873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream
Description: Cream
Study: NCT03420846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OCT Mapped
Description: Presurgical mapping of Basal Cell Carcinoma margins
Study: NCT02632773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive Intervention
Description: Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive Intervention
Description: Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
Study: NCT03228888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of rhytmic acoustic stimuli for gait training
Description: The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of rhytmic acoustic stimuli for gait training
Description: The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player
Study: NCT01250210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel and ethinyl estradiol
Description: pregnancy prevention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel and ethinyl estradiol
Description: pregnancy prevention
Study: NCT01638962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)
Description: The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise
Description: The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
Study: NCT01250210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel and ethinyl estradiol
Description: pregnancy prevention
Study: NCT03716219

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Training
Description: Physical activity in children and adults with asthma.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Physical activity in children and adults with asthma.
Study: NCT02227667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
Study: NCT04270084

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alive-Family
Description: All participants receive lifestyle modification through use of m-health app
Study: NCT00646360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: 400 mg/d of docosahexanoic acid (DHA) during pregnancy
Study: NCT01607983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: 20 parts per million (ppm) of inhaled nitric oxide
Study: NCT03420703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: ultrasound guided erector spinae plane block will be administered to this group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient controlled analgesia device
Description: Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous morphine patient controlled analgesia device
Description: Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
Study: NCT03892811

Intervention type: OTHER
Intervention: Three study conditions
Description: Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
Study: NCT00587379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40 mg atorvastatin pill daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg pill per day
Study: NCT00989833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: 400 yg x 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline
Description: 0.4 mg as-needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline
Description: 0.4 mg as-needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide/formoterol
Description: 160/4.5 yg as-needed
Study: NCT02518477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: progressive resistance training
Study: NCT01109082

Intervention type: PROCEDURE
Intervention: posterior spine fusion
Description: vertebrae are fused to straighten a spinal curve
Study: NCT03023566

Intervention type: DRUG
Intervention: Dotarem
Description: Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
Study: NCT04537728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Healthy Brain Version 2
Description: multimodal lifestyle intervention incorporating mindfulness skills, behavioral principles, and recent research on brain disease risk factors
Study: NCT01228630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloratadd-D
Description: The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra-D
Description: The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
Study: NCT03127969

Intervention type: OTHER
Group type: OTHER
Intervention: Fluidotherapy treatment
Description: fluidotherapy and joint protection and exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Joint protection and exercise
Description: joint protection and exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Joint protection and exercise
Description: joint protection and exercise
Study: NCT03736850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS3006
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s).
Study: NCT03689556

Intervention type: DIAGNOSTIC_TEST
Intervention: FLT PET/CT
Description: Patients will receive 3'-deoxy-3'-\[18F\]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
Study: NCT02167256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530 100mg daily
Description: All patients in experimental group (50%) will be started on 100mg AZD0530 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530 125mg daily
Description: Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50% of patients will receive placebo treatment for the duration of the study.
Study: NCT04004728

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1064 Nd:YAG laser
Description: 1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
Study: NCT02632773

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Directive Intervention
Description: Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Directive Intervention
Description: Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
Study: NCT02140996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-sig-hMUC-1/ecdCD40L vector vaccine
Study: NCT05754242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: 1.5 gr of ascorbic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline solution
Description: 100 ml of 0.9% saline solution
Study: NCT03219996

Intervention type: OTHER
Intervention: prognosis
Description: The participants were divided into two groups based on survival at their hospital discharge.

Intervention type: OTHER
Intervention: prognosis
Description: The participants were divided into two groups based on survival at their hospital discharge.
Study: NCT02110589

Intervention type: DEVICE
Group type: OTHER
Intervention: Epidetect
Description: Topically aplied muscle tonicity monitor (EMG recording)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidetect
Description: Topically aplied muscle tonicity monitor (EMG recording)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidetect
Description: Topically aplied muscle tonicity monitor (EMG recording)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidetect
Description: Topically aplied muscle tonicity monitor (EMG recording)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidetect
Description: Topically aplied muscle tonicity monitor (EMG recording)
Study: NCT04436523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (Delfi Personalized Tourniquet System)
Description: The Delfi Personalized Tourniquet System will be utilized to apply the blood flow restriction protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard rehabilitation
Description: Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.
Study: NCT01111058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD 001)
Description: 10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo